$PACB
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Stock $pacb

$pacb Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000129913023000098 Filed on August 04, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$55.69M	$47.57M	$35.47M
YoY Change	72.36%	34.13%	15.87%
Cost Of Revenue	$37.79M	$32.03M	$19.27M
YoY Change	101.39%	66.17%	14.34%
Gross Profit	$17.90M	$15.55M	$16.19M
YoY Change	32.15%	-4.0%	17.74%
Gross Profit Margin	32.15%	32.68%	45.66%
Selling, General & Admin	$43.43M	$40.57M	$39.25M
YoY Change	18.04%	3.37%	35.07%
% of Gross Profit	242.6%	260.99%	242.4%
Research & Development	$47.51M	$46.17M	$50.35M
YoY Change	0.9%	-8.29%	126.12%
% of Gross Profit	265.41%	297.01%	310.92%
Depreciation & Amortization	$3.850M	$3.061M	$2.551M
YoY Change	49.51%	19.99%	60.64%
% of Gross Profit	21.51%	19.69%	15.75%
Operating Expenses	$100.4M	$88.72M	$84.16M
YoY Change	13.87%	5.42%	63.98%
Operating Profit	-$82.49M	-$73.18M	-$67.97M
YoY Change	10.55%	7.66%	80.9%
Interest Expense	$3.588M	-$3.554M	$3.681M
YoY Change	-2.07%	-196.55%	2.56%
% of Operating Profit
Other Income/Expense, Net	$8.505M	$8.929M	$256.0K
YoY Change	547.75%	3387.89%	59.01%
Pretax Income	-$77.58M	-$69.83M	-$71.39M
YoY Change	0.78%	-2.19%	74.13%
Income Tax	-$10.71M	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$66.87M	-$69.83M	-$71.39M
YoY Change	-13.12%	-2.19%	74.13%
Net Earnings / Revenue	-120.07%	-146.79%	-201.3%
Basic Earnings Per Share	-$0.26	-$0.28	-$0.32
Diluted Earnings Per Share	-$0.26	-$0.28	-$0.32
COMMON SHARES
Basic Shares Outstanding	250.6M shares	249.9M shares	224.5M
Diluted Shares Outstanding	255.0M shares	250.1M shares	224.5M

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$767.8M	$829.9M	$997.6M
YoY Change	-21.23%	-16.82%	-3.53%
Cash & Equivalents	$385.6M	$209.3M	$310.4M
Short-Term Investments	$382.1M	$620.6M	$687.2M
Other Short-Term Assets	$15.80M	$14.05M	$7.957M
YoY Change	18.75%	76.55%	16.3%
Inventory	$68.26M	$67.61M	$36.12M
Prepaid Expenses
Receivables	$30.49M	$24.03M	$27.06M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$882.3M	$935.6M	$970.3M
YoY Change	-3.46%	-3.58%	-18.4%
LONG-TERM ASSETS
Property, Plant & Equipment	$40.34M	$76.76M	$37.96M
YoY Change	3.03%	102.23%	51.83%
Goodwill	$463.8M	$410.0M	$410.0M
YoY Change	13.13%	0.0%
Intangibles	$461.8M	$409.8M	$410.5M
YoY Change	12.56%	-0.18%
Long-Term Investments
YoY Change
Other Assets	$13.00M	$15.57M	$1.205M
YoY Change	1005.78%	1191.7%	1753.85%
Total Long-Term Assets	$1.016B	$912.1M	$905.9M
YoY Change	12.26%	0.69%	1499.18%
TOTAL ASSETS
Total Short-Term Assets	$882.3M	$935.6M	$970.3M
Total Long-Term Assets	$1.016B	$912.1M	$905.9M
Total Assets	$1.898B	$1.848B	$1.876B
YoY Change	4.37%	-1.52%	50.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$16.11M	$16.51M	$12.88M
YoY Change	25.31%	28.17%	170.59%
Accrued Expenses	$34.66M	$36.25M	$25.17M
YoY Change	39.28%	44.01%	9.9%
Deferred Revenue	$22.40M	$25.00M	$32.08M
YoY Change	-27.01%	-22.08%	236.52%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$900.0K	$1.400M
YoY Change
Total Short-Term Liabilities	$184.0M	$271.4M	$84.40M
YoY Change	125.31%	221.59%	85.76%
LONG-TERM LIABILITIES
Long-Term Debt	$892.0M	$891.8M	$896.4M
YoY Change	-0.51%	-0.51%	0.07%
Other Long-Term Liabilities	$1.051M	$42.43M	$2.946M
YoY Change	-40.25%	1340.19%	291.76%
Total Long-Term Liabilities	$1.051M	$934.2M	$2.946M
YoY Change	-40.25%	31611.58%	291.76%
TOTAL LIABILITIES
Total Short-Term Liabilities	$184.0M	$271.4M	$84.40M
Total Long-Term Liabilities	$1.051M	$934.2M	$2.946M
Total Liabilities	$1.135B	$1.206B	$1.194B
YoY Change	-4.84%	0.95%	20.93%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.757B	-$1.690B	-$1.371B
YoY Change	21.35%	23.28%	17.65%
Common Stock	$258.0K	$250.0K	$225.0K
YoY Change	14.16%	11.11%	13.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$763.7M	$642.0M	$681.9M
YoY Change
Total Liabilities & Shareholders Equity	$1.898B	$1.848B	$1.876B
YoY Change	4.37%	-1.52%	50.6%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$66.87M	-$69.83M	-$71.39M
YoY Change	-13.12%	-2.19%	74.13%
Depreciation, Depletion And Amortization	$3.850M	$3.061M	$2.551M
YoY Change	49.51%	19.99%	60.64%
Cash From Operating Activities	-$65.18M	-$41.74M	-$60.56M
YoY Change	3.37%	-31.08%	285.36%
INVESTING ACTIVITIES
Capital Expenditures	$830.0K	$2.268M	-$4.019M
YoY Change	-119.81%	-156.43%	155.99%
Acquisitions
YoY Change
Other Investing Activities	$243.2M	-$96.32M	-$56.26M
YoY Change	318.54%	71.2%	-87.75%
Cash From Investing Activities	$242.3M	-$98.59M	-$60.28M
YoY Change	349.51%	63.55%	-86.92%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-780.0K	-4.715M	455.0K
YoY Change	-124.9%	-1136.26%	-84.21%
NET CHANGE
Cash From Operating Activities	-65.18M	-41.74M	-60.56M
Cash From Investing Activities	242.3M	-98.59M	-60.28M
Cash From Financing Activities	-780.0K	-4.715M	455.0K
Net Change In Cash	176.4M	-145.0M	-120.4M
YoY Change	-3033.47%	20.48%	-74.58%
FREE CASH FLOW
Cash From Operating Activities	-$65.18M	-$41.74M	-$60.56M
Capital Expenditures	$830.0K	$2.268M	-$4.019M
Free Cash Flow	-$66.01M	-$44.01M	-$56.54M
YoY Change	12.14%	-22.17%	299.72%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	pacb	Standard Product Warranty Period StandardProductWarrantyPeriod	P1Y
	us-gaap	Cost Of Revenue CostOfRevenue	61166000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	38292000	usd
	us-gaap	Gross Profit GrossProfit	25307000	usd
	us-gaap	Gross Profit GrossProfit	30348000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	95112000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	103285000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	80391000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	79056000	usd
CY2023Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1975000	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-5438000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	14231000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-6501000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	88721000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	84162000	usd
	us-gaap	Operating Expenses OperatingExpenses	189734000	usd
	us-gaap	Operating Expenses OperatingExpenses	175840000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-73175000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-67969000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-164427000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-145492000	usd
CY2023Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2033000	usd
CY2022Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2033000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	3554000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	3681000	usd
	us-gaap	Interest Expense InterestExpense	7184000	usd
	us-gaap	Interest Expense InterestExpense	7378000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8929000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	256000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	15796000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-23000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-69833000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-71394000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-157848000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-152893000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-69833000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-71394000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-157848000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-152893000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-762000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-1372000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	2079000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-4370000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-70595000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-72766000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-155769000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-157263000	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.64
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	250070000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	223400000	shares
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	692117000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-69833000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-762000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17891000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	641999000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	734578000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-71394000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-1372000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	848000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19226000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	562904000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-157848000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	2079000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	189200000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	9821000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	35843000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	641999000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	790987000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-4370000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-157848000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-152893000	usd
	us-gaap	Depreciation Depreciation	5584000	usd
	us-gaap	Depreciation Depreciation	4591000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	466000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	456000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	3330000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	3412000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	324000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	319000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	35843000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	41722000	usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	6113000	usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-1143000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-6501000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2033000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Inventory Write Down InventoryWriteDown	4295000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	1789000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-45000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-77000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5248000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2817000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	19703000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	14955000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6085000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	340000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4262000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1331000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-5956000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-11357000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2317000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2115000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-4114000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3833000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	539000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	379000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-136432000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-139592000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5989000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7657000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	476879000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	241086000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	595000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	311129000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	230515000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-171144000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-18228000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	189200000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	9821000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	6440000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	6836000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	911000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	770000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	191274000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5670000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-116302000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-152150000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	328311000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	465817000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	212009000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	313667000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	209287000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	310445000	usd
CY2023Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2722000	usd
CY2022Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	3222000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	212009000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	313667000	usd
	us-gaap	Use Of Estimates UseOfEstimates	The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates including, but not limited to, the valuation of inventory, the determination of stand-alone selling prices for revenue recognition, the fair value of contingent consideration, the valuation of acquired intangible assets, the fair value of certain equity awards, the useful lives assigned to long-lived assets, the computation of provisions for income taxes, the borrowing rate used in calculating the operating lease right-of-use assets and operating lease liabilities, the probability associated with variable payments under partnership development agreements, and the valuations related to our convertible senior notes. While the extent of the potential impact of the current macroeconomic conditions on our business is highly uncertain, we considered information available related to assumptions and estimates used to determine the results reported and asset valuations as of June 30, 2023. Actual results could differ materially from these estimates.
CY2023Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	209287000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	325089000	usd
CY2023Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	300000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	300000	usd
CY2023Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2422000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2922000	usd
CY2023Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	832584000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	775540000	usd
CY2023Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	186325000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	172094000	usd
CY2023Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	186325000	usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	172094000	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	172094000	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	14231000	usd
CY2023Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	186325000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	832548000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	80000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2766000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	829862000	usd
CY2023Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	300000	usd
CY2023Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	300000	usd
CY2023Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2422000	usd
CY2023Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2422000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	777083000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	16000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	4781000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	772318000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	300000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	300000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2922000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2922000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue	652574000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue	83386000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	735960000	usd
CY2023Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	25225000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	24139000	usd
CY2023Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	22598000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	14062000	usd
CY2023Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	19785000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	12180000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	67608000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	50381000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	11539000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1760000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9779000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	11539000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1294000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10245000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	387000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	745000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	745000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	745000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	746000	usd
CY2023Q2	pacb	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	6411000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9779000	usd
CY2023Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	30000000	usd
CY2023Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	25000000	usd
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	5000000	usd
CY2023Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	5000000	usd
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P6Y
CY2023Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	4500000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	8000000	usd
CY2023Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1624000	usd
CY2022Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1174000	usd
CY2022Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1651000	usd
CY2021Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	594000	usd
CY2023Q2	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	2247000	usd
CY2022Q2	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	912000	usd
	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	2851000	usd
	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	1865000	usd
CY2023Q2	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1009000	usd
CY2022Q2	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	477000	usd
	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1640000	usd
	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	850000	usd
CY2023Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	2862000	usd
CY2022Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1609000	usd
CY2023Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	2862000	usd
CY2022Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1609000	usd
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	COMMITMENTS AND CONTINGENCIES <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various operating lease agreements, primarily relating to our corporate offices. See </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8 – Commitments and Contingencies</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, subsection titled “Leases”, in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December 31, 2022 for information regarding the Company’s maturity of lease liabilities under its lease agreements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may become involved in legal proceedings, claims and assessments from time to time in the ordinary course of business. We accrue liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that the ultimate outcome of any such pending matters is probable or reasonably estimable, or that these matters will have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of litigation and settlement costs, diversion of management resources, and other factors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see subsection titled </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ief1318ee9ee24960a22a8148d35dc3c7_97" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Legal Proceedings, in Part II, Item 1</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Delaware law and agreements entered into with each of our directors and officers, we may have obligations, under certain circumstances, to hold harmless and indemnify each of our directors and officers against losses suffered or incurred by the indemnified party in connection with their service to us, and judgements, fines, settlements and expenses related to claims arising against such directors and officers to the fullest extent permitted under Delaware law, our bylaws and our certificate of incorporation. We also enter and have entered into indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fundraising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between such third parties and us in connection with such fundraising efforts. To the extent that any such indemnification obligations apply to the lawsuits described above, any associated expenses incurred are included within the related accrued litigation expense amounts. No additional liability associated with such indemnification obligations has been recorded as of June 30, 2023 and December 31, 2022.</span></div>
CY2023Q1	pacb	Public Offering Shares PublicOfferingShares	17500000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	pacb	Offering Share Amount Maximum OfferingShareAmountMaximum	10.00
CY2023Q1	pacb	Public Offering Option To Purchase Additional Shares Period PublicOfferingOptionToPurchaseAdditionalSharesPeriod	P30D
CY2023Q1	pacb	Public Offering Option To Purchase Additional Shares Shares PublicOfferingOptionToPurchaseAdditionalSharesShares	2600000	shares
CY2023Q1	pacb	Percentage Commission Of Gross Proceeds On Sale Of Common Stock Under At Market Offering PercentageCommissionOfGrossProceedsOnSaleOfCommonStockUnderAtMarketOffering	0.0575
CY2023Q1	pacb	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	189700000	usd
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	500000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17891000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19019000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	35843000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	41722000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-69833000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-71394000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-157848000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-152893000	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	250070000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	224499000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	246074000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	223400000	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.64
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.68
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	250070000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	224499000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	246074000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	223400000	shares
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.64
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.68
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	47573000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	35467000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	86473000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	68640000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	47573000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	35467000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	86473000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	68640000	usd
CY2023Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001299130-23-000098-index-headers.html	Edgar Link	pending
0001299130-23-000098-index.html	Edgar Link	pending
0001299130-23-000098.txt	Edgar Link	pending
0001299130-23-000098-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pacb-20230630.htm	Edgar Link	pending
pacb-20230630.xsd	Edgar Link	pending
pacb-20230630x10qxexx311.htm	Edgar Link	pending
pacb-20230630x10qxexx312.htm	Edgar Link	pending
pacb-20230630x10qxexx321.htm	Edgar Link	pending
pacb-20230630x10qxexx322.htm	Edgar Link	pending
pacb-20230630_g1.jpg	Edgar Link	pending
pacb-ex41x2021indenture.htm	Edgar Link	pending
pacb-20230630_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
pacb-20230630_def.xml	Edgar Link	unprocessable
pacb-20230630_lab.xml	Edgar Link	unprocessable
pacb-20230630_pre.xml	Edgar Link	unprocessable
pacb-20230630_htm.xml	Edgar Link	completed
pacb-ex41x2021indenture001.jpg	Edgar Link	pending
pacb-ex41x2021indenture002.jpg	Edgar Link	pending
pacb-ex41x2021indenture003.jpg	Edgar Link	pending
pacb-ex41x2021indenture004.jpg	Edgar Link	pending
pacb-ex41x2021indenture005.jpg	Edgar Link	pending
pacb-ex41x2021indenture006.jpg	Edgar Link	pending
pacb-ex41x2021indenture007.jpg	Edgar Link	pending
pacb-ex41x2021indenture008.jpg	Edgar Link	pending
pacb-ex41x2021indenture009.jpg	Edgar Link	pending
pacb-ex41x2021indenture010.jpg	Edgar Link	pending
pacb-ex41x2021indenture011.jpg	Edgar Link	pending
pacb-ex41x2021indenture012.jpg	Edgar Link	pending
pacb-ex41x2021indenture013.jpg	Edgar Link	pending
pacb-ex41x2021indenture014.jpg	Edgar Link	pending
pacb-ex41x2021indenture015.jpg	Edgar Link	pending
pacb-ex41x2021indenture016.jpg	Edgar Link	pending
pacb-ex41x2021indenture017.jpg	Edgar Link	pending
pacb-ex41x2021indenture018.jpg	Edgar Link	pending
pacb-ex41x2021indenture019.jpg	Edgar Link	pending
pacb-ex41x2021indenture020.jpg	Edgar Link	pending
pacb-ex41x2021indenture021.jpg	Edgar Link	pending
pacb-ex41x2021indenture022.jpg	Edgar Link	pending
pacb-ex41x2021indenture023.jpg	Edgar Link	pending
pacb-ex41x2021indenture024.jpg	Edgar Link	pending
pacb-ex41x2021indenture025.jpg	Edgar Link	pending
pacb-ex41x2021indenture026.jpg	Edgar Link	pending
pacb-ex41x2021indenture027.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PACB
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Stock $pacb

2023 Q3 Form 10-Q Financial Statement

#000129913023000098 Filed on August 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PACB PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Stock $pacb

2023 Q3 Form 10-Q Financial Statement

#000129913023000098 Filed on August 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PACB
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Stock $pacb